WO2004004648A3 - Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use - Google Patents

Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use Download PDF

Info

Publication number
WO2004004648A3
WO2004004648A3 PCT/US2003/021026 US0321026W WO2004004648A3 WO 2004004648 A3 WO2004004648 A3 WO 2004004648A3 US 0321026 W US0321026 W US 0321026W WO 2004004648 A3 WO2004004648 A3 WO 2004004648A3
Authority
WO
WIPO (PCT)
Prior art keywords
nitric oxide
treating
nitrosated
therapeutic agent
disorders
Prior art date
Application number
PCT/US2003/021026
Other languages
French (fr)
Other versions
WO2004004648A2 (en
Inventor
Richard A Earl
Maiko Ezawa
Xinqin Fang
David S Garvey
Ricky D Gaston
Subhash P Khanapure
Gordon L Letts
Chia-En Lin
Ramani R Ranatunge
Stewart K Richardson
Joseph D Schroeder
Cheri A Stevenson
Shiow-Jyi Wey
Original Assignee
Nitromed Inc
Richard A Earl
Maiko Ezawa
Xinqin Fang
David S Garvey
Ricky D Gaston
Subhash P Khanapure
Gordon L Letts
Chia-En Lin
Ramani R Ranatunge
Stewart K Richardson
Joseph D Schroeder
Cheri A Stevenson
Shiow-Jyi Wey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitromed Inc, Richard A Earl, Maiko Ezawa, Xinqin Fang, David S Garvey, Ricky D Gaston, Subhash P Khanapure, Gordon L Letts, Chia-En Lin, Ramani R Ranatunge, Stewart K Richardson, Joseph D Schroeder, Cheri A Stevenson, Shiow-Jyi Wey filed Critical Nitromed Inc
Priority to CA002491127A priority Critical patent/CA2491127A1/en
Priority to AU2003247792A priority patent/AU2003247792B2/en
Priority to EP03763193A priority patent/EP1539729A4/en
Priority to JP2004562619A priority patent/JP2005539089A/en
Publication of WO2004004648A2 publication Critical patent/WO2004004648A2/en
Publication of WO2004004648A3 publication Critical patent/WO2004004648A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
    • C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/28—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms

Abstract

The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.
PCT/US2003/021026 2002-07-03 2003-07-03 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use WO2004004648A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002491127A CA2491127A1 (en) 2002-07-03 2003-07-03 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
AU2003247792A AU2003247792B2 (en) 2002-07-03 2003-07-03 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
EP03763193A EP1539729A4 (en) 2002-07-03 2003-07-03 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
JP2004562619A JP2005539089A (en) 2002-07-03 2003-07-03 Nitrosated non-steroidal anti-inflammatory compounds, compositions and methods of use

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US39311102P 2002-07-03 2002-07-03
US60/393,111 2002-07-03
US39797902P 2002-07-24 2002-07-24
US60/397,979 2002-07-24
US41835302P 2002-10-16 2002-10-16
US60/418,353 2002-10-16
US44979803P 2003-02-26 2003-02-26
US60/449,798 2003-02-26
US45618203P 2003-03-21 2003-03-21
US60/456,182 2003-03-21

Publications (2)

Publication Number Publication Date
WO2004004648A2 WO2004004648A2 (en) 2004-01-15
WO2004004648A3 true WO2004004648A3 (en) 2004-10-28

Family

ID=30119449

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/021026 WO2004004648A2 (en) 2002-07-03 2003-07-03 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use

Country Status (6)

Country Link
US (6) US7163958B2 (en)
EP (1) EP1539729A4 (en)
JP (3) JP2005539089A (en)
AU (2) AU2003247792B2 (en)
CA (1) CA2491127A1 (en)
WO (1) WO2004004648A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371284B2 (en) 2007-06-04 2016-06-21 Techfields Pharma Co., Ltd. Pro-drugs of NSAIAS with very high skin and membranes penetration rates and their new medicinal uses

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355666B1 (en) 2000-06-23 2002-03-12 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
CA2491127A1 (en) * 2002-07-03 2004-01-15 Nitromed, Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
ITMI20021861A1 (en) * 2002-08-29 2004-02-29 Nicox Sa NITROXIALKYL ESTER SYNTHESIS PROCESS OF CARBOXYLIC ACIDS, INTERMEDIATES THAT CAN BE USED IN THAT PROCEDURE AND THEIR PREPARATION.
WO2004032864A2 (en) * 2002-10-07 2004-04-22 Radiorx, Inc. X-nitro compounds, pharmaceutical compositions thereof and uses therof
MXPA06000529A (en) * 2003-07-18 2006-08-11 Santarus Inc Pharmaceutical composition for inhibiting acid secretion.
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005060603A2 (en) * 2003-12-10 2005-07-07 Nitromed, Inc. Nitric oxide releasing pyruvate compounds, compositions and methods of use
US7879817B2 (en) * 2004-01-07 2011-02-01 Seikagaku Corporation Hyaluronic acid derivative and drug containing the same
WO2005070006A2 (en) * 2004-01-22 2005-08-04 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US20090215838A1 (en) * 2005-03-09 2009-08-27 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
WO2007019448A2 (en) * 2005-08-08 2007-02-15 Nitromed, Inc. Nitric oxide enhancing angiotensin ii antagonist compounds, compositions and methods of use
US20070135380A1 (en) 2005-08-12 2007-06-14 Radiorx, Inc. O-nitro compounds, pharmaceutical compositions thereof and uses thereof
US7507842B2 (en) * 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
US20090238763A1 (en) 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
EP2056805B1 (en) * 2006-08-16 2011-05-25 Action Medicines, S.L. Use of 2, 5-dihydroxybenzene derivatives for the treatment of tissue reactive diseases
JP2010532780A (en) * 2007-07-09 2010-10-14 ニコックス エス エイ Use of nitric oxide releasing compounds in the treatment of chronic pain
WO2009012425A2 (en) * 2007-07-19 2009-01-22 Logigal Therapeutics, Inc. Compositions including leukotriene antagonists and nsaids and methods of using the same
EP2048129A1 (en) * 2007-10-12 2009-04-15 Lonza Ag Method for the preparation of organic nitrates
EP2177216A1 (en) * 2008-10-13 2010-04-21 Lacer, S.A. Use of dianhydrohexite mononitrate derivatives as healing agents
CN108191846B (en) 2008-12-04 2021-08-20 于崇曦 High penetration composition and application thereof
US8062653B2 (en) 2009-02-18 2011-11-22 Bezwada Biomedical, Llc Controlled release of nitric oxide and drugs from functionalized macromers and oligomers
WO2010096320A2 (en) * 2009-02-18 2010-08-26 Bezwada Biomedical, Llc Controlled release of nitric oxide and drugs from functionalized macromers and oligomers
BRPI0901298A2 (en) * 2009-04-06 2011-01-04 Ems Sa phthalimide derivatives of nonsteroidal antiinflammatory compounds and / or modulators of tnf- (alpha), process for obtaining them, pharmaceutical compositions containing them and their uses in the treatment of inflammatory diseases
US20100286257A1 (en) * 2009-05-08 2010-11-11 Perricone Nicholas V Methods Of Use Of Nitroalkane Compositions In Dermatologic Applications To Prevent or Treat Skin Aging
US20100286272A1 (en) * 2009-05-08 2010-11-11 Perricone Nicholas V Methods Of Use Of Nitroalkene Compositions In Dermatologic Applications
US20100286271A1 (en) * 2009-05-08 2010-11-11 Perricone Nicholas V Nitro-alkyl Compound Compositions
WO2011012400A2 (en) 2009-07-28 2011-02-03 Nicox S.A. Nitric oxide releasing naproxen
ES2362894B1 (en) * 2009-11-16 2012-05-21 Ferrer Internacional S.A. PREPARATION PROCEDURE FOR �? CIDO 4-NITRO-OXI-METIL-BENZOICO.
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
US8471041B2 (en) * 2010-02-09 2013-06-25 Alliant Techsystems Inc. Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
AR081268A1 (en) * 2010-06-02 2012-07-18 Cardiolynx Ag PIOGLITAZONA NITRATE DERIVATIVES
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US8664247B2 (en) 2011-08-26 2014-03-04 Radiorx, Inc. Acyclic organonitro compounds for use in treating cancer
WO2013052803A2 (en) 2011-10-07 2013-04-11 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
AU2012319071B2 (en) 2011-10-07 2017-08-03 Epicentrx, Inc. Organonitro thioether compounds and medical uses thereof
JP6405312B2 (en) * 2012-10-23 2018-10-17 ニコックス サイエンス アイルランド Quinone-based nitric oxide donor compounds for ophthalmology
US9757529B2 (en) * 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
WO2014111957A1 (en) 2013-01-21 2014-07-24 Apparao Satyam Nitric oxide releasing prodrugs of therapeutic agents
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
WO2017123593A1 (en) 2016-01-11 2017-07-20 Epicentrx, Inc. Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
WO2017137489A1 (en) * 2016-02-12 2017-08-17 Dsm Ip Assets B.V. Anti-methanogenic compositions and uses thereof
CN107459538B (en) * 2016-06-03 2020-10-16 首都医科大学 Diindole-2-propane-2-indole-3-acetyl lysyl glucosamine, synthesis, activity and application thereof
KR102491748B1 (en) 2016-09-29 2023-01-25 케이.엘.알.엠., 엘엘씨 Compositions and methods for the treatment of orthopedic disorders
JP7332469B2 (en) 2016-10-14 2023-08-23 エピセントアールエックス，インコーポレイテッド Sulfoxyalkyl organic nitrogens and related compounds and pharmaceutical compositions for use in medicine
JP7377791B2 (en) 2017-07-07 2023-11-10 エピセントアールエックス，インコーポレイテッド Compositions for parenteral administration of therapeutic agents
US11510901B2 (en) 2018-01-08 2022-11-29 Epicentrx, Inc. Methods and compositions utilizing RRx-001 combination therapy for radioprotection
WO2020163519A1 (en) * 2019-02-06 2020-08-13 K.L.R.M., Llc Compositions and methods for the treatment of constipation and other ailments of the gastrointestinal system
CN110372876A (en) * 2019-07-29 2019-10-25 南京工业大学 A kind of method that solvent evaporation induction prepares metal-organic framework materials
WO2023142996A1 (en) * 2022-01-28 2023-08-03 上海岸阔医药科技有限公司 Method for preventing or treating disease or disorder associated with antineoplastic agent

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780495A (en) * 1993-10-06 1998-07-14 Nicox S.A. Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation
US5844696A (en) * 1995-04-19 1998-12-01 Prodes, S.A. Nitric esters from derivatives of 2-(2,6-dihalophenylamino) phenylacetoxyacetic acid and their preparation process
US5861426A (en) * 1994-05-10 1999-01-19 Nicox S.A. Nitro compounds of the formula A-Xi -NO2 and their compositions having anti-inflammatory, analgesic and anti-thrombotic activities
US6538033B2 (en) * 2000-08-29 2003-03-25 Huntington Medical Research Institutes Nitric oxide donor compounds
US6677374B2 (en) * 1996-06-04 2004-01-13 Queen's University At Kingston Nitrate esters and methods of making same

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1238679B (en) 1990-01-29 1993-09-01 Resa Farma OPTICALLY ACTIVE DERIVATIVE OF D-2- (6-METHOXY-2-NAFTIL) ACID - PROPIONIC AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
GB9200114D0 (en) 1992-01-04 1992-02-26 Scras Dual inhibitors of no synthase and cyclooxygenase
GB2284350B (en) 1992-07-30 1996-08-28 Cal Int Ltd Pharmaceutical compositions comprising esters of organic nitrates and a salicylate
IT1256345B (en) * 1992-08-20 1995-12-01 NITRIC ESTERS OF PHENYLACETIC 2- (2,6-DI-HALO-PHENYLAMIN) DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION
IT1256450B (en) 1992-11-26 1995-12-05 Soldato Piero Del NITRIC ESTERS WITH PHARMACOLOGICAL ACTIVITY AND PROCEDURE FOR THEIR PREPARATION
US5643943A (en) 1994-12-23 1997-07-01 Alcon Laboratories, Inc. Systemic administration of esters and amides of antioxidants which may be used as antioxidant prodrug therapy for oxidative and inflammatory pathogenesis
US5607966A (en) 1994-12-23 1997-03-04 Alcon Laboratories, Inc. Esters and amides of non-steroidal anti-inflammatory carboxylic acids which may be used as anti-oxidants, 5-lipoxygenase inhibitors and non-steroidal anti-inflammatory prodrugs
US5483426A (en) 1994-12-27 1996-01-09 General Motors Corporation Aimable vehicle headlamp assembly
US5703073A (en) 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US6051588A (en) 1995-04-19 2000-04-18 Nitromed Inc Nitroso esters of β-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
US6043232A (en) 1997-07-23 2000-03-28 Nitromed, Inc. Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
DE19515970A1 (en) 1995-05-02 1996-11-07 Bayer Ag Acetylsalicylsäurenitrate
IT1276071B1 (en) 1995-10-31 1997-10-24 Nicox Ltd ANTI-INFLAMMATORY ACTIVITY COMPOSITES
US5653548A (en) * 1996-02-07 1997-08-05 Illinois Tool Works Inc. Method and apparatus for a ball and socket joint
IT1282686B1 (en) 1996-02-26 1998-03-31 Nicox Sa COMPOUNDS ABLE TO REDUCE DRUG TOXICITY
US7115661B1 (en) * 1999-12-29 2006-10-03 Queen's University At Kingston Methods and compositions for mitigating pain
US20050137191A1 (en) * 1996-06-04 2005-06-23 Thatcher Gregory R. Nitrate esters and their use for mitigating cellular damage
IT1288123B1 (en) 1996-09-04 1998-09-10 Nicox Sa USE OF NITRO-DERIVATIVES FOR URINARY INCONTINENCE
DE19651243A1 (en) 1996-12-10 1998-06-18 Basf Ag Amphiphilic graft polymers based on graft bases containing N-vinylcarboxamide units, process for their preparation and their use
DE19753776A1 (en) 1997-12-04 1999-06-10 Bosch Gmbh Robert Measuring device for contactless detection of an angle of rotation
US6113301A (en) 1998-02-13 2000-09-05 Burton; John E. Disengageable pivot joint
IT1298338B1 (en) 1998-03-05 1999-12-20 Nicox Sa PHARMACEUTICAL COMPOSITIONS FOR THE ULCER
IT1299198B1 (en) 1998-03-05 2000-02-29 Nicox Sa NITRATED SALTS OF ANTI-ULCER DRUGS
SE9802333D0 (en) 1998-06-29 1998-06-29 Astra Pharma Prod Novel combination
IT1303672B1 (en) 1998-07-28 2001-02-23 Nicox Sa NITRATED SALTS OF DRUGS ACTIVE IN BONE DISORDERS
EP1126838A4 (en) 1998-10-30 2005-02-16 Nitromed Inc Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
IT1307928B1 (en) 1999-01-26 2001-11-29 Nicox Sa METHOD OF SYNTHESIS OF NITROXYMETHYLPHENYL ESTERS OF ASPIRINE DERIVATIVES.
IT1308633B1 (en) * 1999-03-02 2002-01-09 Nicox Sa NITROSSIDERIVATI.
IT1311923B1 (en) 1999-04-13 2002-03-20 Nicox Sa PHARMACEUTICAL COMPOUNDS.
IT1311922B1 (en) 1999-04-13 2002-03-20 Nicox Sa PHARMACEUTICAL COMPOUNDS.
IT1311921B1 (en) 1999-04-13 2002-03-20 Nicox Sa PHARMACEUTICAL COMPOUNDS.
IT1311924B1 (en) 1999-04-13 2002-03-20 Nicox Sa PHARMACEUTICAL COMPOUNDS.
US6244735B1 (en) * 1999-05-11 2001-06-12 John E. Burton Headlamp adjuster with anti-rotation ball stud head
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
IT1312115B1 (en) 1999-06-24 2002-04-04 Nicox Sa AMORPHOUS COMPOUNDS AND RELATED PHARMACEUTICAL COMPOSITIONS
ITMI991517A1 (en) 1999-07-09 2001-01-09 Nicox Sa PROCEDURE FOR OBTAINING EXTERNAL NITROXYMETHYL FENYL OF SALICYLIC ACID DERIVATIVES
IT1313596B1 (en) 1999-08-04 2002-09-09 Nicox Sa PROCESS FOR THE PREPARATION OF NITROXIALKYL ESTERS OF NAPROXENE
IT1314184B1 (en) 1999-08-12 2002-12-06 Nicox Sa PHARMACEUTICAL COMPOSITIONS FOR THE THERAPY OF STRESS-OXIDATIVE CONDITIONS
TWI262791B (en) 1999-10-27 2006-10-01 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
US6552078B2 (en) 1999-10-27 2003-04-22 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
SE0000773D0 (en) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US6433317B1 (en) 2000-04-07 2002-08-13 Watlow Polymer Technologies Molded assembly with heating element captured therein
CA2406947A1 (en) 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
AU2001275036A1 (en) 2000-06-02 2001-12-17 Medinox, Inc. Protected forms of a combination of pharmacologically active agents and uses therefor
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US6355666B1 (en) 2000-06-23 2002-03-12 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
SE0002476D0 (en) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
IT1318673B1 (en) 2000-08-08 2003-08-27 Nicox Sa DRUGS FOR SEXUAL DYSFUNCTIONS.
IT1318674B1 (en) 2000-08-08 2003-08-27 Nicox Sa DO IT FOR INCONTINENCE.
JP2002118295A (en) 2000-10-11 2002-04-19 Sumitomo Special Metals Co Ltd Thermoelectric conversion material, manufacturing method thereof and thermoelectric conversion element
IT1319202B1 (en) * 2000-10-12 2003-09-26 Nicox Sa DRUGS FOR INFLAMMATORY-BASED DISEASES.
IT1320176B1 (en) 2000-12-22 2003-11-26 Nicox Sa SOLID DISPERSIONS OF NITRATED ACTIVE INGREDIENTS.
EP1219306A1 (en) 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
CN1133626C (en) * 2001-01-08 2004-01-07 南京长澳医药科技有限公司 Diclofenac coupled derivative and its synthesizing process and inflammation relieving action
SE0100901D0 (en) * 2001-03-15 2001-03-15 Astrazeneca Ab New composition
ITMI20010985A1 (en) 2001-05-15 2002-11-15 Nicox Sa DRUGS FOR ALZHEIMER DISEASE
ITMI20011240A1 (en) 2001-06-13 2002-12-13 Nicox Sa DRUGS FOR VASCULOPATHIES
ITMI20011307A1 (en) 2001-06-21 2002-12-21 Nicox Sa DRUGS FOR EPILEPSY
ITMI20011308A1 (en) 2001-06-21 2002-12-21 Nicox Sa DRUGS FOR CHRONIC PAIN
ITMI20011744A1 (en) * 2001-08-09 2003-02-09 Nicox Sa DRUGS FOR VASCULOPATHIES
SE0102993D0 (en) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
ITMI20020773A1 (en) 2002-04-11 2003-10-13 Nicox Sa DRUGS FOR THE TREATMENT OF ARTHRITIS
US20040077691A1 (en) 2002-06-21 2004-04-22 Medinox, Inc. Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
ITMI20021392A1 (en) 2002-06-25 2003-12-29 Nicox Sa PHARMACEUTICAL FORMS FOR THE ORAL ADMINISTRATION OF LIQUID DRUGS AT AMBIENT TEMPERATURE EQUIPPED WITH BETTER BIOAVAILABILITY
ITMI20021399A1 (en) 2002-06-25 2003-12-29 Nicox Sa CYCLOOXYGENASE INHIBITORS 2
CA2491127A1 (en) * 2002-07-03 2004-01-15 Nitromed, Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
ITMI20021861A1 (en) 2002-08-29 2004-02-29 Nicox Sa NITROXIALKYL ESTER SYNTHESIS PROCESS OF CARBOXYLIC ACIDS, INTERMEDIATES THAT CAN BE USED IN THAT PROCEDURE AND THEIR PREPARATION.
RU2322434C2 (en) 2002-09-20 2008-04-20 Никокс С.А. Method for preparing no-donor compounds, such as no-donor diclofenac

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780495A (en) * 1993-10-06 1998-07-14 Nicox S.A. Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation
US5861426A (en) * 1994-05-10 1999-01-19 Nicox S.A. Nitro compounds of the formula A-Xi -NO2 and their compositions having anti-inflammatory, analgesic and anti-thrombotic activities
US5844696A (en) * 1995-04-19 1998-12-01 Prodes, S.A. Nitric esters from derivatives of 2-(2,6-dihalophenylamino) phenylacetoxyacetic acid and their preparation process
US6677374B2 (en) * 1996-06-04 2004-01-13 Queen's University At Kingston Nitrate esters and methods of making same
US6538033B2 (en) * 2000-08-29 2003-03-25 Huntington Medical Research Institutes Nitric oxide donor compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371284B2 (en) 2007-06-04 2016-06-21 Techfields Pharma Co., Ltd. Pro-drugs of NSAIAS with very high skin and membranes penetration rates and their new medicinal uses

Also Published As

Publication number Publication date
US7754772B2 (en) 2010-07-13
EP1539729A2 (en) 2005-06-15
US20050222243A1 (en) 2005-10-06
US8222277B2 (en) 2012-07-17
US8304409B2 (en) 2012-11-06
CA2491127A1 (en) 2004-01-15
AU2003247792B2 (en) 2009-09-24
AU2003247792A1 (en) 2004-01-23
JP2010265292A (en) 2010-11-25
WO2004004648A2 (en) 2004-01-15
US20040024057A1 (en) 2004-02-05
US7883714B2 (en) 2011-02-08
US20100137291A1 (en) 2010-06-03
US20100093671A1 (en) 2010-04-15
US7163958B2 (en) 2007-01-16
US20110098253A1 (en) 2011-04-28
US8088762B2 (en) 2012-01-03
US20100093708A1 (en) 2010-04-15
AU2009250989A1 (en) 2010-01-14
JP2005539089A (en) 2005-12-22
JP2010280665A (en) 2010-12-16
EP1539729A4 (en) 2008-02-20

Similar Documents

Publication Publication Date Title
WO2004004648A3 (en) Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
HK1257517A1 (en) 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
WO2004002409A3 (en) Cyclooxygenase-2 selective inhibitors, compositions and methods of use
NO20044054L (en) Administration of agents for the treatment of inflammation
WO2004012659A3 (en) Nitrosated proton pump inhibitors, compositions and methods of use
WO2002098352A3 (en) PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
WO2002046129A3 (en) Inhibitors of histone deacetylase
BR0307050A (en) Compound, pharmaceutical composition, methods for treating prostaglandin d2 mediated diseases, for treating nasal congestion, for treating allergic asthma, and for treating allergic rhinitis, pharmaceutically acceptable salt, and use of a compound or salt
NO20035496D0 (en) Substituted Sulfonamide Compounds, Methods for Their Use as a Drug for the Treatment of CNS Disorders, Overweight and Type II Diabetes
CY2009002I1 (en) USE OF AMINO ACID ANTISPLASMICS FOR THE THERAPEUTIC TREATMENT OF PAIN
WO2006127591A3 (en) Organic nitric oxide enhancing salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
NO20052698D0 (en) 4 (phenylpiperazinylmethyl) benzamide derivatives and their use in the treatment of pain and gaseous tract disorders.
NO20041833L (en) Heterocyclic compounds for use in the treatment of urinary tract disorders
WO2001038311A3 (en) Pyrimidine derivatives as selective inhibitors of cox-2
BR0316458A (en) Compound, pharmaceutical composition, method of treating or preventing disease, method for enhancing cognition in a healthy patient, and use of a compound
NZ533269A (en) Inhibitors of cytosolic phospholipase A2
EE200300363A (en) Use of N- (Pyridinyl) -1H-Indole-1-Amine Compounds in the manufacture of a medicament for the treatment of diseases and conditions associated with myelin loss
NO20025394L (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
WO2004002420A3 (en) Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
WO2004010945A3 (en) Cyclooxygenase- 2 selective inhibitors, compositions and methods of use
AU2003278664A1 (en) 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
DK1309322T3 (en) Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders
NO20032006L (en) Use of melagatran for the manufacture of a medicament for the treatment of ischemic disorders
SE0102639D0 (en) Novel compounds
HUP0300876A3 (en) Use of diclofenac for the manufacture of medicament for the topical treatment of burns

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003247792

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2491127

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004562619

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003763193

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003763193

Country of ref document: EP